Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer
Terminated
University of Wisconsin, Madison
Phase 2
2012-02-01
The purpose of this study is to assess the change in quality of life over a 6 month period
between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes
related to androgen deprivation therapy.
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Completed
XenoPort, Inc.
Phase 4
2012-06-01
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently
approved in the United States for the treatment of adults with moderate-to-severe primary
Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy, tolerability,
and safety of GEn at lower doses (450 and 300 mg/day) as well as the already approved dose of
600 mg/day versus placebo for the treatment of subjects with moderate to severe primary RLS.
This study is being conducted as a post-marketing commitment (PMC) as a condition of the
approval of HORIZANT tablets (NDA 022399).
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
Terminated
Gillette Children's Specialty Healthcare
Phase 2
2012-04-01
This study is a prospective, randomized, double blind, placebo controlled, crossover clinical
trial looking at whether gabapentin can provide symptom relief for chronic irritability in
neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and
safe for children with chronic irritability that persists despite identification and
appropriate management of symptom sources.
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
Terminated
Scott Schwantes, M.D.
Phase 2
2012-04-01
This study is a prospective, randomized, double blind, placebo controlled, crossover clinical
trial looking at whether gabapentin can provide symptom relief for chronic irritability in
neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and
safe for children with chronic irritability that persists despite identification and
appropriate management of symptom sources.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
